|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
STAR Pharmaceutical Limited
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name STAR Pharmaceutical Limited Headquarters 21/F Haitian Building Midhill Garden 1 Jinmaozhong Road; Haikou; Hainan; 570125 Legal Address 300 Beach Road, #33-04/06 The Concourse; Singapore; Singapore; 199555 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational ISIN CODE : SG1S90928817 Financial Auditors: Horwath First Trust (2008) Incorporation Date: January 10, 2005 Tel: (86898) 36338555 |
|
Company Description |
| The Group is engaged in the manufacture and sale of both western and TCM-formulated prescription drugs. Its products include antibiotics, cerebrovascular drugs and cardiovascular drugs. |
Company Analysis |
| According to the Consolidated - Non-Audited financial statement for the first three cumulated quarters of 2012, total net operating revenues increased with 0.10%, from CNY 66,237 thousands to CNY 66,301 thousands. Operating result increased from CNY 616 thousands to CNY 9,240 thousands which means 1400.00% change. The results of the period reached CNY 4,359 thousands at the end of the period against CNY -2,216 thousands last year. Return on equity (Net income/Total equity) went from -0.93% to 1.87%, the Return On Asset (Net income / Total Asset) went from -0.65% to 1.36% and the Net Profit Margin (Net Income/Net Sales) went from -3.35% to 6.57% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 44.03% compared to 48.60% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 1.08 to 1.21 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Q3C (cons) |
2012 Q2C (cons) |
|
 | ||
| Non-Audited | Non-Audited | |
| ||
| WVB Company Financials | WVB Company Financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
320,789 |
335,636 |
| ||
Current Assets |
88,124 |
86,374 |
| ||
Total Liabilities |
102,629 |
119,440 |
| ||
Shareholders Equity |
233,115 |
231,269 |
| ||
Current Liabilities |
72,637 |
89,310 |
| ||
| * All the accounts are in CNY. | ||
Income Statement
| ||
Total Operating Revenue |
66,301 |
41,630 |
| ||
Operational Profit (Loss) |
9,240 |
5,718 |
| ||
Net Profit (Loss) |
4,359 |
2,395 |
| ||
| * All the accounts are in CNY. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
1.36% |
0.71% |
| ||
Annualised Return on Assets (ROA) |
1.81% |
1.42% |
| ||
Return on Equity (ROE) |
2% |
1.11% |
| ||
Annualised Return on Equity (ROE) |
2.67% |
2.22% |
| ||
Return on Sales (ROS) |
6.65% |
5.81% |
| ||
Return on Capital |
2% |
1.11% |
| ||
Gross Profit Margin |
51.02% |
50.1% |
| ||
Operating Profit Margin |
21.65% |
22.29% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
48.89x |
68.88x |
| ||
Inventory Turnover |
3.17x |
2.39x |
| ||
Current asset turnover |
0.74x |
0.48x |
| ||
Fixed-asset turnover |
0.28x |
0.17x |
| ||
Asset Turnover |
0.20x |
0.12x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
9,234 |
5,719 |
| ||
EBITDA |
14,973 |
9,569 |
| ||
Enterprise value |
65,717 |
78,616 |
| ||
Enterprise Value / EBITDA |
4.39 |
8.22 |
| ||
Bookvalue (BV) |
300,789 |
295,636 |
| ||
Net Cash |
-64,867 |
-80,341 |
| Liquidity Ratios | ||
| ||
Current Ratio |
121.32% |
96.71% |
| ||
Quick ratio |
107.4% |
87.07% |
| ||
Doom's day ratio |
10.7% |
10.04% |
| Leverage Ratios | ||
| ||
Leverage ratio |
147.04% |
155.25% |
| ||
Interest Coverage Ratio |
239.66% |
187.08% |
| ||
Debt to equity |
47.04% |
55.25% |
| ||
Debt to total assets |
31.99% |
35.59% |
| ||
Long Term Debt to Capital |
17.14% |
17.21% |
| ||
Debt / Enterprise Value |
30.43% |
50.88% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
2.57 |
3.40 |
| ||
Market Cap / Net cash |
-0.59 |
-0.40 |
| Trend Ratios | ||
| ||
Revenue Trend |
99.81% |
90.84% |
| ||
Net Income Trend |
-196.71% |
480.92% |
| ||
Operating Income Trend |
1,144.24% |
223.75% |
| ||
 |